BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
6 results:

  • 1. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial.
    Zapatero A; Álvarez A; Guerrero A; Maldonado X; González San Segundo C; Cabeza MA; Martín de Vidales C; Solé JM; Pedro Olivé A; Casas F; Boladeras A; Vázquez de la Torre ML; Vara S; Calvo FA
    Radiother Oncol; 2021 Jul; 160():115-119. PubMed ID: 33964325
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. IL-4 protects tumor cells from anti-cd95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
    Conticello C; Pedini F; Zeuner A; Patti M; Zerilli M; Stassi G; Messina A; Peschle C; De Maria R
    J Immunol; 2004 May; 172(9):5467-77. PubMed ID: 15100288
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer.
    Stattin P; Westin P; Damber JE; Bergh A
    Br J Cancer; 1998 Feb; 77(4):670-5. PubMed ID: 9484828
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival.
    Gansler TS; Hardman W; Hunt DA; Schaffel S; Hennigar RA
    Hum Pathol; 1997 Jun; 28(6):686-92. PubMed ID: 9191002
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
    Kuban DA; el-Mahdi AM; Schellhammer PF
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.